Dexamethasone Does Not Improve Vision in Persistent Diabetic Macular Edema Dexamethasone Does Not Improve Vision in Persistent Diabetic Macular Edema

Adding dexamethasone to continued ranibizumab treatment reduces retinal thickness but does not improve vision in patients with persistent diabetic macular edema (DME), according to results from a phase 2 randomized trial.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news

Related Links:

ConclusionsFor patients with Type 2 diabetes, team-based care improves blood glucose, blood pressure, and lipid levels.
Source: American Journal of Preventive Medicine - Category: International Medicine & Public Health Source Type: research
Publication date: July 2019Source: American Journal of Preventive Medicine, Volume 57, Issue 1Author(s): Community Preventive Services Task Force
Source: American Journal of Preventive Medicine - Category: International Medicine & Public Health Source Type: research
Source: BMJ Comments - Category: General Medicine Source Type: forums
Publication date: July 2019Source: Trends in Endocrinology &Metabolism, Volume 30, Issue 7Author(s): Naila Rabbani, Paul J. ThornalleyHexokinase-2 (HK2) was recently found to produce increased metabolic flux through glycolysis in hyperglycemia without concurrent transcriptional or other functional regulation. Rather, stabilization to proteolysis by increased glucose substrate binding produced unscheduled increased glucose metabolism in response to high cytosolic glucose concentration. This produces abnormal increases in glycolytic intermediates or glycolytic overload, driving cell dysfunction and vulnerability to the d...
Source: Trends in Endocrinology and Metabolism - Category: Endocrinology Source Type: research
Publication date: Available online 17 June 2019Source: The Lancet Diabetes &EndocrinologyAuthor(s):
Source: The Lancet Diabetes and Endocrinology - Category: Endocrinology Source Type: research
Osteoporosis drugs appear to help women older than 80 years with multiple morbidities and osteoporosis; very elderly women with high fracture risk but no osteoporosis may benefit less, a study found.Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Family Medicine/Primary Care News Source Type: news
Publication date: Available online 17 June 2019Source: Pharmacological ResearchAuthor(s): Du Lei, Li Chengcheng, Qian Xuan, Chen Yibing, Wang Lei, Yang Hao, Li Xizhi, Li Yuan, Yin Xiaoxing, Lu QianAbstractDiabetic nephropathy (DN) is one of the most common microvascular complications of diabetes and the leading cause of end-stage renal disease. The proliferation of glomerular mesangial cells (MCs) is a common and prominent pathological change of DN, which takes place at the early stage. Quercetin, a bioflavonoid compound, possesses therapeutic efficacy in cardiovascular and kidney diseases via anti-tumour, anti-oxidation,...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
This study aims to investigate the antidiabetic effects of the hot water extract of C. nitida seeds in type 2 diabetic rats.MethodsType 2 diabetic rats were orally administered with low (150 mg/kg bw) and high (300 mg/kg bw) doses of the hot water extract for 6 wk and thereafter, blood glucose, insulin level, lipid profile, pancreatic β-cell function, perfusion and morphology, redox imbalance, glycolytic and cholinergic enzymes, as well as of caspase-3 and Nrf2 expressions were measured.ResultsTreatment with the extract led to significant depleted levels of blood glucose, triglycerides, LDL-c, fructosamine, ALT,...
Source: Journal of Ethnopharmacology - Category: Drugs & Pharmacology Source Type: research
[2-25-2015] In an effort to reduce the serious risk of infection spread through sharing of multi-dose diabetes pen devices intended for single patient use only, the U.S. Food and Drug Administration (FDA) is requiring additional label warnings prohibiting sharing of these injectable medicines.
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news
[12-16-2015] The U.S. Food and Drug Administration (FDA) is eliminating the Risk Evaluation and Mitigation Strategy (REMS) for rosiglitazone-containing type 2 diabetes medicines, which are approved as Avandia, Avandamet, Avandaryl, and generics.
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news
More News: Dexamethasone | Diabetes | Endocrinology | Health | Lucentis | Ranibizumab Injection | Vitamin A